In our retrospective study, we found that the later-line regimen of an anti-PD-1/PD-L1 antibody plus anlotinib yielded a promising survival outcome in NSCLC patients with EGFR mutations. This evidence concerns the gene CD274 and non-small cell lung carcinoma.